Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19 : Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study
Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
ClinicalTrials.gov - (2021) vom: 10. Sept. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 13, 2021, Last updated: September 15, 2021 |
---|
Study ID: |
NCT04416464 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003413381 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003413381 | ||
003 | DE-627 | ||
005 | 20230425221539.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003413381 | ||
035 | |a (UBBS_Klinische_Studien)NCT04416464 | ||
035 | |a (UBBS_Klinische_Studien)QoL_ICU_COVID | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19 |b Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 13, 2021, Last updated: September 15, 2021 | ||
520 | |a Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period. | ||
650 | 2 | |a Infection | |
650 | 2 | |a Coronavirus Infections | |
650 | 4 | |a Medical Condition: Quality of Life, Long-term Outcomes, Coronavirus Infection, Morality, Rehospitalization | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Active, not recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 10. Sept. |
773 | 1 | 8 | |g year:2021 |g day:10 |g month:09 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04416464 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 10 |c 09 |